After the black box warning: Dramatic changes in ED use of droperidol [1]

American Journal of Emergency Medicine

Volumn 23, Issue 2, 2005, Pages 196-

  Jacoby, Jeanne L ^a   Fulton, Jessica ^a   Cesta, Mark ^a   Heller, Michael ^a  

^a ST LUKE S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROPERIDOL; HALOPERIDOL; KETAMINE; LORAZEPAM; ONDANSETRON;

DRUG USE; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY MONITORING; EMERGENCY WARD; HEALTH SURVEY; LETTER; MEDICAL PRACTICE; NAUSEA; PHYSICIAN; PRIORITY JOURNAL; VOMITING;

EID: 14844329045     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2004.09.019     Document Type: Letter

References (5)

1. M.E. Mullins, and K. Van Zwieten Unexpected cardiovascular deaths are rare with therapeutic doses of droperidol Am. J. Emerg. Med. 22 2004 27 28
2. K. Zwieten, and M.E. Mullins Droperidol and the black box warning Ann. Emerg. Med. 43 1 2004 139 140
3. R.J. Meyer FDA "black box" labeling Ann. Emerg. Med. 41 2003 559 560
4. Lenzer J, Solomon RC. The droperidol dilemma: is the FDA's black box warning necessary? ACEP News 2002; 3, 8.
5. Inapsine (droperidol injection), black box warning, Taylor Pharmaceuticals, and Akorn Co, 11/01.